Co-Diagnostics

Co-Diagnostics, Inc. engages in the development and innovation of molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. Its diagnostics systems enable very rapid, low-cost, molecular testing for organisms and genetic diseases by automating historically complex procedures in both the development and administration of tests. The company was founded by Brent C. Satterfield and Dwight Howard Egan on April 18, 2013 and is headquartered in Salt Lake City, UT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Co-Diagnostics reports Q1 results, focuses on growth and innovation

Co-Diagnostics reported mixed financial results for Q1 2024, with revenue decrease but gross profit increase.
The company is strategically focused on commercialization efforts, product development, and managing expenses for growth.
Despite facing challenges such as net losses and operational complexities, Co-Diagnostics remains optimistic about future opportunities.
With a strong cash position and ongoing FDA submissions, Co-Diagnostics is poised for potential revenue growth and market expansion.

Co-Diagnostics reports Q3 revenue decline, focuses on global expansion

Co-Diagnostics faces financial challenges with a significant net loss in Q3 2024 but maintains a strong focus on advancing its testing platforms and expanding manufacturing capabilities.
Strategic opportunities in international market expansion and test development supported by grants present avenues for growth and market penetration.
Efforts to manage cash position through efficient spending and operational efficiencies underscore the company's commitment to future commercial success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SALT LAKE CITY , Nov. 30, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that Co-Diagnostics will be presenting on December 1, 2022, at the Piper Sandler 34th Annual Healthcare Conference, held November 29-December 31, 2022, in New York City, New York. Dwight Egan, Company CEO, and Dr. Kirk Ririe, President of the Company's subsidiary, will be conducting a presentation discussing recent and expected Company progress along with its forthcoming Co-Dx PCR diagnostic platform.

Co-Diagnostics, Inc. to Present at the Piper Sandler 34th Annual Healthcare Conference on December 1, 2022

SALT LAKE CITY , Nov. 14, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be hosting a booth this week at the MEDICA 2022 trade fair in Düsseldorf, Germany from 15-17 November. After more than 40 years, MEDICA has become the largest medical trade fair in the world, attracting thousands of exhibitors from more than 50 countries.

Co-Diagnostics, Inc. to Host Booth at MEDICA 2022 Trade Fair in Düsseldorf, Germany

Co-Diagnostics Inc (NASDAQ:CODX) posted financial results for the third quarter that revealed ample cash on hand, giving the company scope to further advance its Co-Dx PCR Home testing platform for infectious diseases.   As of September 30, 2022, the Salt Lake City, Utah-based molecular diagnostics company, had cash, equivalents, and marketable securities of $86.5 million.

Co-Diagnostics ends 3Q with $86.5M in cash; makes significant progress on its Co-Dx PCR Home platform

Co-Diagnostics, Inc. (NASDAQ:CODX ) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Dan Bohrer - VP, Finance and Accounting Dwight Egan - CEO Brian Brown - CFO Conference Call Participants Theodore O'Neill - Litchfield Hills Research Operator Good afternoon, and welcome to the Co-Diagnostics, Inc. Third Quarter 2022 Earnings Results Conference Call. [Operator Instructions] Please note, this event is being recorded.

Co-Diagnostics, Inc. (CODX) Q3 2022 Earnings Call Transcript

CoDiagnostics, Inc. (CODX) delivered earnings and revenue surprises of 33.33% and 24.53%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

CoDiagnostics, Inc. (CODX) Reports Q3 Loss, Lags Revenue Estimates

Nearing commencement of clinical evaluations for the Co-Dx PCR Home platform COVID-19 test volumes continue to impact third quarter results SALT LAKE CITY , Nov. 10, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today financial results for the third quarter ended September 30, 2022. Third Quarter 2022 Financial Results: Revenue of $5.1 million, down from $30.1 million during the prior year period, but an increase of 1.4% from the current year second quarter Gross profit of $4.3 million, representing 84.9% of consolidated revenue Operating loss of $6.5 million compared to operating income of $13.6 million a year ago, due to lower sales volumes and continued investments into research and development for the Co-Dx PCR Home Platform Net loss of $1.4 million, compared to a net income of $11.5 million in the prior-year third quarter, representing a loss of $0.04 per fully diluted share Adjusted EBITDA loss of $4.1 million Repurchased 2.9 million shares during the third quarter at an average price of $3.61 per share Cash, cash equivalents, and marketable securities of $86.5 million as of September 30, 2022 Cash flow from operations of $10.6 million for the nine months ended September 30, 2022, of which $1.1 million was generated in the third quarter Dwight Egan, Co-Diagnostics' Chief Executive Officer, remarked, "While our third quarter results were impacted by lower demand for our COVID-19 test, we made significant progress on our Co-Dx PCR Home™ platform which is nearing its final stages.

Co-Diagnostics, Inc. Reports Third Quarter 2022 Financial Results

SALT LAKE CITY , Nov. 3, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that the Company is hosting a booth this week at the Association for Molecular Pathology ("AMP") annual expo, held November 1-5 in Phoenix, AZ. The conference website describes AMP as the leading organization in the field of molecular diagnostics, with their annual meeting being considered the "premier gathering" of molecular professionals to explore how cutting-edge technology and developments in molecular testing and diagnostics continue to have a major impact on patient care.

Co-Diagnostics, Inc. to Host Booth at AMP This Week in Phoenix, AZ

Co-Diagnostics Inc (NASDAQ:CODX) has announced the appointment of Mark Poritz as the company's new chief scientific officer (CSO). Poritz is a Harvard University-educated molecular biologist with more than 30 years of experience in the application of polymerase chain reaction (PCR) and related methods to gene cloning, drug discovery, infectious disease diagnostics and aptamer selection.

Co-Diagnostics appoints veteran molecular biologist Mark Poritz as its new chief scientific officer

SALT LAKE CITY , Nov. 1, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx™" or the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it is pleased to welcome Mark Poritz, PhD as the Company's new Chief Scientific Officer ("CSO"). Dr. Poritz is a Harvard University and UC San Francisco educated molecular biologist with more than 30 years of experience in the application of PCR and related methods to gene cloning, drug discovery, infectious disease diagnostics and aptamer selection, who has also served as a reviewer for more than 30 different NIH/NIAID study sections focusing on infectious disease diagnostics.

Co-Diagnostics, Inc. Appoints Dr. Mark Poritz as New Chief Scientific Officer

SALT LAKE CITY , Oct. 27, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its third quarter 2022 results on Thursday, November 10, 2022, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m.

CO-DIAGNOSTICS, INC. ANNOUNCES THIRD QUARTER 2022 EARNINGS RELEASE DATE AND WEBCAST

SALT LAKE CITY , Oct. 26, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that the Company will be hosting a booth this week at Africa Health/Medlab Africa in Johannesburg, South Africa on October 26-28, 2022. The conference is the largest gathering of healthcare companies, technology, products and services in the sub-Saharan region, catering to an audience of professionals from the South African Development Community region and around the world, including distributors, government representatives, laboratory executives, and purchasing/procurement managers, who attend to meet with world-class suppliers and manufacturers.

Co-Diagnostics, Inc. to Host Booth at Medlab Africa on Oct 26-28 in South Africa

SALT LAKE CITY , Oct. 19, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that the Company will be hosting booths this week at IDWeek 2022 in Washington, D.C., and at Asia Health/Medlab Asia in Bangkok, Thailand.

Co-Diagnostics, Inc. to Host Booths at Conferences in Washington, D.C. and Bangkok, Thailand

NEW YORK , Oct. 19, 2022 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Co-Diagnostics, Inc.. Shareholders who purchased shares of CODX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Co-Diagnostics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 17, 2022 - (NASDAQ: CODX)

San Francisco, California--(Newsfile Corp. - October 17, 2022) - Hagens Berman urges Co-Diagnostics, Inc. (NASDAQ: CODX) investors who suffered significant losses to submit your losses now. Class Period: May 12, 2022 - Aug. 11, 2022Lead Plaintiff Deadline: Oct. 17, 2022Visit: www.hbsslaw.com/investor-fraud/CODXContact An Attorney Now: CODX@hbsslaw.com844-916-0895Co-Diagnostics, Inc. (NASDAQ: CODX) Securities Fraud Class Action: Throughout the Class Period, Defendants repeatedly touted Co-Diagnostics' Logix Smart COVID-19 Test and, as

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts Co-Diagnostics (CODX) Investors of Today's Lead Plaintiff Deadline in Securities Class Action

Los Angeles, California--(Newsfile Corp. - October 17, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Co-Diagnostics, Inc. ("Co-Diagnostics" or "the Company") (NASDAQ: CODX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

DEADLINE TODAY: The Schall Law Firm Encourages Investors in Co-Diagnostics, Inc. with Losses of $100,000 to Contact the Firm

New York, New York--(Newsfile Corp. - October 16, 2022) - Levi & Korsinsky, LLP notifies investors in Co-Diagnostics, Inc. ("Co-Dx" or the "Company") (NASDAQ: CODX) of a class action securities lawsuit.The lawsuit on behalf of Co-Dx investors has been commenced in the the United States District Court for the Southern District of New York.

Co-Dx Class Action: Levi & Korsinsky Reminds Co-Diagnostics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 17, 2022 - CODX

New York, New York--(Newsfile Corp. - October 16, 2022) - Pomerantz LLP announces that a class action lawsuit has been filed against Co-Diagnostics, Inc. (NASDAQ: CODX) ("Co-Dx" or the "Company") and certain of its officers.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Co-Diagnostics, Inc. of Class Action Lawsuit and Upcoming Deadline - CODX

NEW YORK , Oct. 14, 2022 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Co-Diagnostics, Inc. (NASDAQ: CODX) between May 12, 2022 and August 11, 2022, both dates inclusive (the "Class Period"), of the important October 17, 2022  lead plaintiff deadline. SO WHAT: If you purchased Co-Diagnostics securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

CODX FINAL DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Co-Diagnostics, Inc. Investors to Secure Counsel Before Important October 17 Deadline in Securities Class Action - CODX

NEW YORK , Oct. 14, 2022 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Co-Diagnostics, Inc. (NASDAQ: CODX). To receive updates on the lawsuit, fill out the form: https://claimyourloss.com/securities/co-diagnostics-inc-loss-submission-form-2/?id=32597&from=4 This lawsuit is on behalf of a class of all persons and entities who purchased the publicly traded securities of Co-Dx during the period of May 12, 2022 through the close of the market on August 11, 2022 (4:00 p.m.

CODX SHAREHOLDER ALERT: Jakubowitz Law Reminds Co-Dx Shareholders of a Lead Plaintiff Deadline of October 17, 2022

PHILADELPHIA--(BUSINESS WIRE)--Kaskela Law LLC announces that it is investigating Co-Diagnostics, Inc. (“Co-Diagnostics” or the Company) (NASDAQ: CODX) on behalf of the Company's long-term investors.

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Co-Diagnostics, Inc. (CODX) and Encourages Long-Term CODX Investors to Contact the Firm

New York, New York--(Newsfile Corp. - October 11, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Co-Diagnostics, Inc. (NASDAQ: CODX) between May 12, 2022 and August 11, 2022, both dates inclusive (the "Class Period"), of the important October 17, 2022 lead plaintiff deadline.

CODX Deadline Notice: ROSEN, Leading Investor Counsel, Encourages Co-Diagnostics, Inc. Investors to Secure Counsel Before Important October 17 Deadline in Securities Class Action - CODX

New York, New York--(Newsfile Corp. - October 9, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Co-Diagnostics, Inc. (NASDAQ: CODX) between May 12, 2022 and August 11, 2022, both dates inclusive (the "Class Period"), of the important October 17, 2022 lead plaintiff deadline.

CODX Final Notice: ROSEN, Top Ranked Investor Counsel, Encourages Co-Diagnostics, Inc. Investors to Secure Counsel Before Important October 17 Deadline in Securities Class Action - CODX

NEW YORK , Oct. 6, 2022 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Co-Diagnostics, Inc. ("Co-Dx" or the "Company") (NASDAQ: CODX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Co-Dx investors who were adversely affected by alleged securities fraud.

CODX LAWSUIT ALERT: Levi & Korsinsky Notifies Co-Diagnostics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

NEW YORK , Oct. 4, 2022 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Co-Diagnostics, Inc. (NASDAQ: CODX) alleging that the Company violated federal securities laws. This lawsuit is on behalf of a class of all persons and entities who purchased the publicly traded securities of Co-Dx during the period of May 12, 2022 through the close of the market on August 11, 2022 (4:00 p.m.

CODX ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of October 17, 2022 in the Class Action Filed on Behalf of Co-Diagnostics, Inc. Shareholders

NEW YORK , Oct. 3, 2022 /PRNewswire/ -- Attention Co-Diagnostics, Inc. ("Co-Dx") (NASDAQ: CODX) shareholders: The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors. This lawsuit is on behalf of a class of all persons and entities who purchased the publicly traded securities of Co-Dx during the period of May 12, 2022 through the close of the market on August 11, 2022 (4:00 p.m.

News for Co-Diagnostics Stock (CODX)